CNX Therapeutics to expand CNS portfolio through the acquisition of two established brands from Eisai

Eisai 

London, April 2nd, 2024 - CNX Therapeutics Limited (“CNX Therapeutics”), a speciality pharmaceutical company with a portfolio of medicines for the treatment of central nervous system (CNS) disorders and hospital emergencies in over 40 countries worldwide, is pleased to announce that it has successfully completed the acquisition of two CNS products from Eisai S.A.S. (“Eisai”), the French sales subsidiary of Eisai Co., Ltd. the international pharmaceutical company.  

CNX Therapeutics has acquired two medicines; Loxapac® (loxapine) and Parkinane LP® (trihexyphenidyl chloride) which are used to treat psychological disorders and Parkinson’s disease respectively. More specifically:   

• Loxapac®, used in adults and children over 15 for the treatment of acute and chronic psychotic states and states of agitation, aggressiveness and anxiety associated with psychotic disorders of certain short-term personality disorders. Available in France and Algeria.

• Parkinane LP®, used for the treatment of Parkinson’s disease and neuroleptic-induced parkinsonian syndrome. Available in France and Algeria.

The acquisition of these products adds to CNX Therapeutics’ portfolio of CNS products and further expands their presence across Europe. Acquiring these well-established products also supports CNX Therapeutics’ mission to improve access to medicines that are critical to the well-being of patients. 

CNX Therapeutics’ Vice President of Corporate Development, Ben Moore commented, “Through this strategic acquisition we are excited to expand our European footprint – building our presence in the French market. This addition to our portfolio of CNS medicines underscores our commitment to improving the lives of patients suffering from psychiatric and neurological disorders. We are eager to leverage our expertise and resources to maximise the potential of these therapies”. 

Under the terms of the agreement, CNX Therapeutics will pay €56.5m to Eisai for the two medicines, excluding inventory and working capital.  

Following the signature of the agreement, a transition period has opened during which the required implementation steps will be carried out in order for CNX to become able to operate directly the business, including the regulatory steps for the transfer of the relevant marketing authorisations and exploitant status. 

CNX Therapeutics was acquired by Inflexion Private Equity, a leading mid-market private equity firm, in 2021. 

CNX Therapeutics was advised on this transaction by Trowers & Hamlins, UGGC Avocats, BDO, Alira Health and Grant Thornton.  

Contact: communications@cnx-therapeutics.com 

About CNX Therapeutics 

CNX Therapeutics is a speciality pharmaceutical company committed to improving the lives of patients by providing access to essential medicines. CNX commercialises and distributes a portfolio of pharmaceuticals for neurological, psychiatric and hospital emergencies in over 40 countries worldwide, both directly and through strategic partnerships.  

CNX is an attractive partner for companies who are looking for a pan-European partner for Central Nervous System (CNS) and hospital injectable products, which is committed to the highest standards of ethics and sustainability. CNX has a pioneering approach to Environment, Social and Governance (ESG), which forms a key part of its mission. For more information on CNX Therapeutics, please visit: www.cnx-therapeutics.com 

About Eisai EMEA 

At Eisai, everything we do is dedicated to giving our first thought to patients and their families through our human health care (hhc) philosophy. We are the European hub of Tokyo-based Eisai Co. Ltd., forming part of a multinational team working across a global network of R&D facilities, manufacturing sites and marketing subsidiaries.   

Our collective passion and dedication to patient care is the driving force behind our efforts to discover and develop innovative medicines in a variety of therapeutic areas in which a high unmet medical need remains, including oncology and neurology.  

Our mission is clear; we strive to make a significant long-lasting contribution to society in an ethical, compliant and sustainable way by embodying our hhc philosophy in everything we do.  

For more information about Eisai in the EMEA region please visit: www.eisai.eu